NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Syndax Pharmaceuticals logo
$8.74 -0.39 (-4.27%)
As of 03:51 PM Eastern

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Advanced

Key Stats

Today's Range
$8.72
▼
$9.27
50-Day Range
$8.56
▼
$18.80
52-Week Range
$8.41
▼
$25.59
Volume
1.41 million shs
Average Volume
1.89 million shs
Market Capitalization
$786.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.40
Consensus Rating
Moderate Buy

Company Overview

Syndax Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines for cancer and related serious diseases. Its research programs include therapies that target cancer-driving pathways, including menin and the colony-stimulating factor 1 receptor (CSF-1R).

The company’s medicines include Revuforj (revumenib), approved in the United States for certain adults and children aged one year and older with relapsed or refractory acute leukemia involving a KMT2A translocation. Syndax also developed Niktimvo (axatilimab-csfr), approved for adults with chronic graft-versus-host disease after at least two prior lines of systemic therapy; it commercializes the medicine in collaboration with Incyte.

Founded in 2005, Syndax is based in Waltham, Massachusetts, and conducts drug development and commercialization activities in the United States and internationally. Michael A. Metzger has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Syndax Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

SNDX MarketRank™: 
2.08133643708 of 5 stars

Syndax Pharmaceuticals scored higher than 42% of companies evaluated by MarketBeat, and ranked 596th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Syndax Pharmaceuticals has a consensus price target of $41.40, representing about 359.5% upside from its current price of $9.01.

  • Amount of Analyst Coverage

    Syndax Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Syndax Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($2.09) to ($1.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syndax Pharmaceuticals is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syndax Pharmaceuticals is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    22.08% of the float of Syndax Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 6.41.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Syndax Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syndax Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Syndax Pharmaceuticals has a news sentiment score of -0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $113,680.00 in company stock.

  • Percentage Held by Insiders

    4.80% of the stock of Syndax Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Syndax Pharmaceuticals has minimal institutional ownership at this time.

  • Read more about Syndax Pharmaceuticals' insider trading history.
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNDX Stock News Headlines

A little-known law has been quietly applied to your savings for years.
Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.tc pixel
See More Headlines

SNDX Stock Analysis - Frequently Asked Questions

Syndax Pharmaceuticals' stock was trading at $21.01 at the start of the year. Since then, SNDX shares have decreased by 57.1% and is now trading at $9.01.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) posted its quarterly earnings results on Monday, November, 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.05. Syndax Pharmaceuticals's revenue for the quarter was up 81.9% on a year-over-year basis.
Read the conference call transcript
.

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Syndax Pharmaceuticals' top institutional shareholders include Goldman Sachs Group Inc. (6.13%), State Street Corp (5.17%), Candriam S.C.A. (1.89%) and Algert Global LLC (1.24%). Insiders that own company stock include Michael A Metzger, Dennis Podlesak, Keith A Goldan, Neil Gallagher and Nicholas AJ Botwood.
View institutional ownership trends
.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Delta Air Lines (DAL), Walt Disney (DIS) and Verastem (VSTM).

Company Calendar

Last Earnings
11/02/2026
Today
11/20/2026
Investor update
12/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SNDX
CIK
1395937
Employees
298
Year Founded
2005

Price Target and Rating

High Price Target
$57.00
Low Price Target
$31.00
Potential Upside/Downside
+370.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$285.42 million
Net Margins
-72.32%
Pretax Margin
-72.32%
Return on Equity
-804.38%
Return on Assets
-34.93%

Debt

Debt-to-Equity Ratio
38.95
Current Ratio
4.69
Quick Ratio
4.37

Sales & Book Value

Annual Sales
$289.68 million
Price / Sales
2.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.19) per share
Price / Book
-46.32

Miscellaneous

Outstanding Shares
90,028,000
Free Float
85,707,000
Market Cap
$792.25 million
Optionable
Optionable
Beta
0.48

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:SNDX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners